Skip to main content
Erschienen in: International Journal of Hematology 5/2017

23.02.2017 | Progress in Hematology

Guest editorial: Connecting multiple aspects of hematologic malignancies toward creation of new therapeutics

verfasst von: Fumihiko Ishikawa

Erschienen in: International Journal of Hematology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Excerpt

The field of malignant stem cell research was pioneered by acute myeloid leukemia (AML) research. Every hematologist must recall an original article in Nature, 1994, in which Dr. Dick and his colleagues found preferential engraftment in immune-compromised mice by CD34+CD38 AML cells [1]. This exciting report on phenotypic and functional heterogeneity within human AML led the way to investigations into potential heterogeneity in solid tumors as well as diverse hematologic malignancies. …
Literatur
1.
Zurück zum Zitat Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645–8.CrossRefPubMed Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645–8.CrossRefPubMed
2.
Zurück zum Zitat Jan M, Snyder TM, Corces-Zimmerman MR, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med. 2012;4:149ra118.CrossRefPubMedPubMedCentral Jan M, Snyder TM, Corces-Zimmerman MR, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med. 2012;4:149ra118.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Corces-Zimmerman MR, Hong WJ, Weissman IL, et al. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA. 2014;111:2548–53.CrossRefPubMedPubMedCentral Corces-Zimmerman MR, Hong WJ, Weissman IL, et al. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA. 2014;111:2548–53.CrossRefPubMedPubMedCentral
4.
5.
Zurück zum Zitat Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–98.CrossRefPubMedPubMedCentral Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–98.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477–87.CrossRefPubMedPubMedCentral Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477–87.CrossRefPubMedPubMedCentral
7.
8.
Zurück zum Zitat Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126:9–16.CrossRefPubMedPubMedCentral Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126:9–16.CrossRefPubMedPubMedCentral
Metadaten
Titel
Guest editorial: Connecting multiple aspects of hematologic malignancies toward creation of new therapeutics
verfasst von
Fumihiko Ishikawa
Publikationsdatum
23.02.2017
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 5/2017
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-017-2200-x

Weitere Artikel der Ausgabe 5/2017

International Journal of Hematology 5/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.